1. Signaling Pathways
  2. PI3K/Akt/mTOR
  3. PI3K
  4. PI3Kα Isoform
  5. PI3Kα Inhibitor

PI3Kα Inhibitor

PI3Kα Inhibitors (142):

Cat. No. Product Name Effect Purity
  • HY-10108
    LY294002
    Inhibitor 99.92%
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively.
  • HY-15244
    Alpelisib
    Inhibitor 99.86%
    Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor.
  • HY-70063
    Buparlisib
    Inhibitor 99.90%
    Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.
  • HY-101562
    Inavolisib
    Inhibitor 98.94%
    GDC-0077 (RG6114) is a potent, orally available, and selective PI3Kα inhibitor (IC50=0.038 nM).
  • HY-50673
    Dactolisib
    Inhibitor 99.94%
    Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively.
  • HY-128333
    PI3K/mTOR Inhibitor-4
    Inhibitor
    PI3K/mTOR Inhibitor-4 is an orally active pan-class I PI3K/mTOR inhibitor.
  • HY-12279A
    Umbralisib tosylate
    Inhibitor
    Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively.
  • HY-12279B
    Umbralisib sulfate
    Inhibitor
    Umbralisib (TGR-1202) sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively.
  • HY-13026
    Idelalisib
    Inhibitor 99.78%
    Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
  • HY-15346
    Copanlisib
    Inhibitor 99.50%
    Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively.
  • HY-50094
    Pictilisib
    Inhibitor 99.80%
    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
  • HY-100716
    Eganelisib
    Inhibitor 99.69%
    Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM.
  • HY-17044
    Duvelisib
    Inhibitor 99.89%
    Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.
  • HY-13898
    Taselisib
    Inhibitor 99.86%
    Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.
  • HY-13228
    YM-201636
    Inhibitor 98.01%
    YM-201636 is a potent and selective PIKfyve inhibitor with an IC50 of 33 nM.
  • HY-10297
    Omipalisib
    Inhibitor 99.93%
    Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively.
  • HY-10115
    PI-103
    Inhibitor 98.93%
    PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2.
  • HY-13522
    Fimepinostat
    Inhibitor 99.95%
    Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.
  • HY-12279
    Umbralisib
    Inhibitor 98.69%
    Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively.
  • HY-15177
    PF-04691502
    Inhibitor 99.64%
    PF-04691502 is a potent and selective inhibitor of PI3K and mTOR.